Liraglutide

Liraglutide is a prescription medicine injected under the skin once a day. It belongs to a drug class called GLP-1 receptor agonists, which copy a gut hormone your body already makes. US labeling covers two jobs: improving blood sugar control in type 2 diabetes, and, at a higher daily dose sold under a separate brand, long term weight management. It is prescription only, and there is no tablet version of this molecule.

This page explains, in everyday language, what the official label says, what side effects people actually report, which warnings matter most, and what drives the monthly self-pay cost. It is a reference page, not a treatment plan. If you are weighing up telehealth programs that prescribe GLP-1 medicines, the Choosing A GLP-1 Program guide covers that decision separately.

What liraglutide is, and who it is for

Short answer: it is an FDA-approved daily injection that mimics the hormone GLP-1. Doctors prescribe it alongside diet and exercise to lower blood sugar in adults and children aged 10 and older with type 2 diabetes. A higher-dose product with the same active ingredient is approved for chronic weight management in adults and in some adolescents.

Both versions come in a multi-dose pen with a small, fine needle. You inject into the stomach, thigh or upper arm. The pens are not interchangeable, because the dose steps and maximum doses differ. The label is blunt about one thing: never share a pen with another person, even after changing the needle, because of infection risk.

The medicine is not insulin and does not replace it. It is not approved for type 1 diabetes. Because it lowers blood sugar mainly when blood sugar is high, the risk of dangerous lows is lower on its own than with insulin, though that risk rises when it is combined with certain other diabetes drugs. For patient-facing background on the condition itself, the federal diabetes institute keeps a plain overview of type 2 diabetes basics.

How the drug works in the body

GLP-1 is a hormone released by your gut after you eat. It tells the pancreas to release insulin when glucose is high, and it turns down glucagon, a hormone that pushes the liver to release stored sugar. It also slows how fast the stomach empties, and it acts on appetite centres in the brain. Natural GLP-1 breaks down within minutes.

This drug is a modified copy that resists that rapid breakdown, so a single daily injection keeps blood levels reasonably steady over 24 hours. That is the practical difference from the newer weekly GLP-1 medicines: the molecule stays active for hours rather than days, so it has to be taken every day.

Two effects explain most of what patients notice. Slower stomach emptying and reduced appetite signalling mean smaller meals feel filling sooner, which is why nausea and early fullness are the most common complaints. Better insulin timing and less glucagon mean lower fasting and after-meal glucose readings, which is why HbA1c usually falls. A widely cited peer-reviewed review of liraglutide in weight management research sets out the appetite and satiety evidence in more detail.

Approved uses and how dosing is stepped up

Under current US labeling, the diabetes products are indicated as an add-on to diet and exercise to improve blood sugar control in adults and children aged 10 and older with type 2 diabetes. The original diabetes brand label also includes reducing the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease. The weight-management product is indicated for long term weight control in adults with obesity, or with excess weight plus a weight-related health problem, and in adolescents who meet specific weight and body mass index criteria.

The label also sets limits. Products containing this ingredient should not be combined with each other. It has not been studied in people with a history of pancreatitis in the same way as other options, and it is not a substitute for insulin in people who need insulin. A drug reference maintained by a major US clinic summarises the approved subcutaneous uses and cautions.

Because eligibility for the weight-management version is tied partly to body mass index, it helps to know your own number before an intake appointment.

Dosing is always individualised by a prescriber, but the general shape of a start is consistent across labels:

1. Screening first, including personal and family thyroid history, pancreatitis history, kidney function and any other diabetes medicines you take.
2. A deliberately low starting dose for the first week, which is meant to settle your stomach rather than to treat anything.
3. Weekly step-ups toward a target dose, with the diabetes products capping lower than the weight-management product.
4. Slowing or pausing a step-up if nausea or vomiting is hard to tolerate, on a clinician’s instruction.
5. Follow-up checks: blood sugar or HbA1c for diabetes, weight and blood pressure for weight management, plus a review of side effects.

Never change your own dose or dose schedule based on a web page. The pen instructions and your prescriber’s directions are the authority.

Side effects: the common ones and the ones to act on

Most side effects are digestive and most are worst in the first days after each dose increase. Commonly reported effects include nausea, vomiting, diarrhoea, constipation, indigestion, reduced appetite, burping, headache, tiredness and dizziness. Injection site redness or itching happens too. These often ease as your body adjusts, though some people cannot get past them.

Serious problems are much less common, but they are the reason follow-up matters. Reported serious risks across GLP-1 receptor agonists include acute pancreatitis, gallbladder disease including gallstones, kidney injury triggered by dehydration from vomiting or diarrhoea, severe allergic reactions and low blood sugar when the drug is combined with insulin or an insulin-releasing pill. The weight-management labeling also asks prescribers to monitor for new or worsening depression or suicidal thoughts, and notes a small average rise in resting heart rate. The consumer drug page from the National Library of Medicine lists the reported side effects and warning signs in patient language.

When to get medical help

Contact a clinician promptly, or use emergency care, if you have severe or persistent stomach pain that may spread to your back, especially with vomiting. Other reasons to seek care without waiting: signs of an allergic reaction such as swelling of the face or throat, trouble breathing, a rash with dizziness; a lump or swelling in the neck, hoarseness, trouble swallowing or lasting shortness of breath; symptoms of very low blood sugar such as shaking, sweating, confusion or fainting; and signs of dehydration or a drop in urine output. Yellowing skin, pale stools or right upper belly pain can point to a gallbladder problem. None of this is a diagnosis; it is a prompt to be checked.

Boxed warning, contraindications and drug interactions

This drug carries a boxed warning, the strongest warning the FDA uses. In rodent studies, the medicine caused thyroid C-cell tumours in a way that depended on dose and treatment length. Whether it causes those tumours, including medullary thyroid carcinoma, in humans is not known, because the human relevance of the rodent findings has not been established. That uncertainty drives a hard rule: the drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, or with the genetic syndrome multiple endocrine neoplasia type 2. It is also contraindicated after a serious hypersensitivity reaction to the active ingredient. The full prescribing information for each product is published on the government label archive, DailyMed’s prescribing information database.

Other label warnings to raise with a prescriber include a history of pancreatitis, gallbladder disease, diabetic retinopathy, or reduced kidney function. Pregnancy matters here: weight loss offers no benefit during pregnancy, and treatment for weight management is not recommended if you are pregnant or trying to conceive. Anyone who could become pregnant should discuss timing and contraception before starting.

Interactions fall into three practical groups:

• Insulin and insulin-releasing pills such as sulfonylureas. Combining them raises the risk of hypoglycaemia, so prescribers often reduce those doses. Never adjust them yourself.
• Oral medicines that need predictable absorption. Because the stomach empties more slowly, the timing or effect of some tablets can shift. Tell your prescriber about every oral drug you take, including thyroid medicine and contraceptives.
• Procedures and anaesthesia. Slower stomach emptying is now a standard question before sedation. Tell your surgical or dental team that you are on a GLP-1 medicine well ahead of any procedure.

Alcohol, other appetite medicines and over the counter supplements belong on the same disclosure list. So does any other GLP-1 product, since stacking two is not recommended.

Brands, generic pens and compounded versions

Two US brand names carry this ingredient: one for type 2 diabetes and one, at a higher daily dose, for chronic weight management. That is why the same molecule shows up in two very different conversations. The diabetes brand and the weight brand are not interchangeable, and a prescription written for one is not filled with the other.

Generic liraglutide injection also exists. Generic pens are approved through the same FDA route as other generics, which means the agency reviewed them for the same active ingredient, strength and route as the reference product. Which generics are on the market, and which brand they reference, changes over time; you can check current approvals in the FDA’s own database of approved drug products and generics. A generic pen is usually the cheapest legitimate route to the same approved molecule, when your pharmacy stocks one.

Compounded versions are a different category. Compounded preparations are mixed by a pharmacy and are not FDA-approved: no agency has reviewed that specific product for safety, effectiveness or manufacturing quality before it is sold, even though the active ingredient itself is approved elsewhere. Federal rules also limit compounding copies of approved drugs. Compounding pharmacies fall into two buckets: 503A pharmacies, which prepare medicines for individual patients under state board oversight, and 503B outsourcing facilities, which register with the FDA and follow stricter manufacturing standards. The FDA has published specific concerns about unapproved GLP-1 drugs used for weight loss, and its wider guidance on human drug compounding rules explains the two categories. If a program offers a compounded GLP-1, ask which pharmacy fills it, which category it sits in, whether the ingredient is a salt form or the base molecule, and what testing is done on each batch.

Cost without insurance, and what actually moves it

Self-pay pricing is the reason most people land on a page like this. Across the telehealth programs tracked on this site, the lowest recurring self-pay figure for a liraglutide program is $99 a month, and the middle of the tracked range sits at $162. Those figures are US dollars per month on a cash-pay basis, and advertised prices move often, so treat any number as a starting point for your own check rather than a fixed rate.

Several things push a monthly total up or down:

• Brand versus generic versus compounded. Brand pens list highest. Generic pens are usually cheaper. Compounded vials sit outside the approved-product market entirely, with different risks attached.
• Dose strength and quantity. A daily injection means more drug per month than a weekly one, and higher target doses use up a pen faster, so a month at the top of the range costs more than a month at the start.
• Which pharmacy fills it, and whether the program uses one it owns, contracts with, or simply sends your script to.
• What the monthly figure includes. Some programs bundle the clinician visit, messaging, dose changes and shipping. Others charge a membership fee, then bill medication separately, then add labs on top.
• Introductory versus renewal pricing. A first-month rate is not always the rate in month four. Read the renewal terms before you commit.

Because a daily injection is a long term expense, it is worth doing the annual arithmetic before you start rather than after three refills.

If you want to see how the same molecule is priced across different programs and pharmacy routes, the Telehealth Provider Directory and the Free Savings Report both show the comparison in one place, and the wider Medication Index covers the alternatives.

Insurance, prior authorization and what to verify

Nothing on this page can tell you whether your plan pays. Coverage for GLP-1 medicines is decided plan by plan, and the same insurer can cover one indication and exclude another. In practice, prescriptions written for type 2 diabetes tend to face fewer hurdles than prescriptions written for weight management, and many plans exclude weight-loss drugs outright or wrap them in conditions.

Prior authorization is the norm rather than the exception, and first-pass denials are common. Plans commonly ask for documented diagnosis codes, recent lab values, weight history, a record of previous treatments tried, and sometimes participation in a lifestyle program. Appeals succeed sometimes, and they take paperwork.

Two other points to keep straight. First, a telehealth program that says it can bill your insurer is describing billing capability, not a promise of coverage. Second, when a program quotes a monthly price with insurance, that figure normally means the plan or membership fee only. Your copay, coinsurance and deductible sit on top and vary by plan and state. Call the number on your card, ask for the pharmacy benefit team, and ask specifically about the product and indication your prescriber intends to use.

Daily liraglutide versus weekly semaglutide and tirzepatide

This is the comparison people search for most, usually phrased as whether it is the same drug as Ozempic. It is not. Ozempic contains semaglutide. The three GLP-1 families in common use differ in molecule, schedule and labeled brand.

Yes, weight loss does occur with the higher-dose daily product: that is what it is approved for, used with diet and exercise. Average results differ between molecules, and published head-to-head trials indexed in PubMed research on semaglutide versus liraglutide generally point to greater average weight reduction with weekly semaglutide. That, plus the convenience of one injection a week, explains why prescribing has shifted toward the newer options and why this older molecule now feels less popular. It has not stopped being useful. It has a longer track record, generic pens exist, and daily dosing can suit people who titrate slowly or tolerate a smaller daily dose better than a large weekly one.

For side by side detail on the alternatives, see the guides on Weekly Semaglutide Explained and Tirzepatide Uses And Risks. The federal obesity information service also keeps a neutral summary of prescription medications for weight management.

What to ask before your first pen, and how to compare programs

Bring these questions to the appointment, whether it is in person or by video:

• Given my history, is this the right molecule, or would a weekly option or a non-GLP-1 approach suit me better?
• Does anyone in my family have medullary thyroid carcinoma or multiple endocrine neoplasia type 2?
• Which of my current medicines need adjusting, especially insulin or sulfonylureas?
• What labs do you want before starting, and how often after?
• What should I do on a day when nausea or vomiting stops me eating or drinking normally?
• How slowly can we step up the dose if I struggle?
• What is the plan if it does not work, or if I need to stop?

For the program itself, the variables worth comparing are narrower than the marketing suggests: whether you speak to a prescriber or only fill a form, whether dose changes and messaging are included, whether labs are required and who pays for them, which pharmacy fills the script, whether refills arrive reliably, how cancellation works, and whether the price you see is an introductory rate. Patient scores on this site weight value, treatment breadth, platform ease, trust signals, accessibility and support, and the Scoring Methodology Page sets out how those parts are combined. Cost calculators for dosing and spending sit in Free Health Calculators, and ongoing analysis of the GLP-1 market lives in the Latest Editorial Analysis.

Authoritative sources

• FDA approved product and generic listings, useful for checking which pens are currently approved: Dr